Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2019 Ingredion Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to introduce your host for today's conference call Ms. Tiffany Willis. You may go ahead, ma'am.

Thank you, Kevin. Good morning and welcome to Ingredion's fourth quarter and full year 2019 earnings call. I'm Tiffany Willis, Vice President of Investor Relations and Corporate Communications Officer. I'm thrilled to be with you today and I look forward to working with all of you in the months and years to come, as we discuss Ingredion's performance. Here with me today are Jim Zallie, our President and CEO; and Jim Gray, our Executive Vice President and Chief Financial Officer. Our results were issued this morning in a press release that can be found on our website ingredion.com in the Investor section. The slides accompanying this presentation can also be found on the website and were posted a few hours ago for your convenience. As a reminder, our comments within this presentation may contain forward-looking statements. These statements are subject to various risks and uncertainties. Actual results could differ materially from those predicted in the forward-looking statements, and Ingredion is under no obligation to update them in the future, as, or if circumstances change. Additional information concerning factors that could cause actual results to differ materially from those discussed during today's conference call or in this morning's press release, can be found in the Company's most recently filed Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. During this call, we also refer to certain non-GAAP financial measures, including adjusted earnings per share, adjusted operating income, adjusted effective tax rate and adjusted cash flow from operations, which are reconciled to U.S. GAAP measures in Note 2 non-GAAP information included in our press release and in today's presentation's appendix. And with that, I'm pleased to turn the call over to Jim Zallie.

Thank you, Tiffany, and welcome to everyone joining us today. In 2019, we made excellent progress executing on the four pillars supporting our strategy in a rapidly changing food and beverage industry. Our strategic investments aligned with consumer preferences and trends and our strong relationships with customers are creating exciting new opportunities. Across the specialties portfolio, we are building and expanding and with the improvements and operating efficiency and the delivery of cost savings, we've created a more agile organization. We're advancing growth initiatives in each of our platforms. And at the same time, we continue to take actions to address and mitigate macroeconomic challenges. Let me turn to our fourth quarter results. For the quarter, global net sales delivered modest growth. Absent $55 million of negative foreign exchange impacts, net sales were up 4% versus the prior year. Adjusted operating income for the quarter was down 5% year-over-year, however, up 1% absent foreign exchange translation impacts. For the full year, our global net sales were down 1%. Absent $292 million of negative foreign currency impacts, net sales were up 4% versus the prior year. Adjusted operating income was down 8% versus prior year and down 2% absent foreign exchange translation impacts. This year, we progressed our driving growth roadmap by advancing on trend especially growth platforms. Our specialties portfolio now represents 30% of our total net sales. Specialty growth was led primarily by starch-based texturizers as well as sugar reduction and specialty sweeteners. Starch-based texturizers delivered low single digit net sales growth driven by contributions from our tapioca and potato starch portfolios, as well as the acquisition and integration of Western Polymer. As for our sugar reduction and specialty sweeter platform, we delivered high-single digit net sales growth during the quarter, driven by greater consumer demand for non-GMO sweeteners…

Thank you, Jim. Net sales of $1.549 billion were up 1% for the quarter versus prior year. Gross profit margin was flat as favorable price mix offset higher input costs and foreign exchanges impacts. Reported and adjusted operating incomes for $170 million and $158 million respectively. Reported operating income was slightly higher resulting from a $22 million benefit from indirect tax credits recorded in Brazil, partially offset by $16 million of restructuring charges associated with customer and $4 million of integration and other costs. Our reported and adjusted earnings per share were both $1.61. Fourth quarter net sales of $1.549 billion were up 1% versus prior year. Unfavorable FX of $56 million was primarily attributable to weaker currency valuations. Volume was flat or favorable price max accounted for $68 million of net sales increase. In North America, net sales were up slightly versus prior year. Price mix was up 3% as a result of product mix and price pass-through of higher corn cost. This was partially offset by volume share as we see ceased wet milling at our Stockton facility in November 2018. In South America, net sales were up 7% with volume up 9% across the region. Price mix was up 16% and our teams took price increases to recapture the foreign exchange impacts, felt in Argentina, Brazil and Colombia. APAC net sales declined 4% due to lower sales primarily in ASEANI as customers benefited from the pass-through of lower tapioca root cost. EMEA net sales decline 1% due to foreign exchange impacts, partially offset by favorable pricing actions in Pakistan. For the quarter, reported and adjusted operating income increased $12 million and decreased $9 million, respectively. The decrease in adjusted operating income was primarily due to Asia-Pacific factors that Jim has previously highlighted. Corporate cost increased by $3…

Thanks, Jim. 2019 was a year in which we made meaningful progress, positioning the Company for improved performance and profitability. We advanced the five growth platforms in our driving growth roadmap and continue to increase the share of our specialty net sales as a percentage of our total portfolio. Across our markets, our specialty investments are aligned with consumer trends and our strong relationships with customers are creating new opportunities and greater demand, further positioning us for growth. We could not have achieved this without the hard work, commitment and focus of our 11,000 employees around the world who bring their best to the Company each and every day. For the 11th consecutive year, we were recognized by Fortune Magazine as one of the world's most admired companies. We are also proud to have been included in Bloomberg's Gender-Equality Index for the third consecutive year. These distinctions are a testament to our purpose driven culture of bringing together the potential of people, nature and technology to make life better. We will be presenting at CAGNY next week on February 18th, and we look forward to discussing our driving growth agenda in more detail. Thank you and now let's open the call for questions.

[Operator Instructions] Our first question comes from Ben Bienvenu with Stephens Inc.

I want to start asking about kind of a tough one and I know it's open-ended and a moving target, but coronavirus, if you could talk about what you have seen to the extent you've seen anything so far in 1Q, whether it's any demand destruction or logistical challenges that are impacting costs directly on your business? And then, indirectly obviously, we've seen the impact on soybean meal and soybean oil prices, which impact your co-product value, but if you could just talk about as it stands right now kind of what the direct and indirect impacts are on your business as it relates to coronavirus?

Yes. So, Jim, let me take that and you can add any commentary. So, first of all, we have two manufacturing facilities in China, both of those facilities are respectively about 850 kilometers from Wuhan in different provinces. The impact so far that we have seen is like most companies, a delay mandated by the government for employees that went away for Chinese New Year to return back. And then, in some cases some mixed signals around quarantine time periods. That being said, one of our factories has been operating uninterrupted. The other factory has been operating one line only with an abbreviated staff and it has been delayed in its production by approximately two weeks. All of our employees are safe. None of our employees thus far that we know of have contracted coronavirus and the office has a protocol in place in regards to how to operate the sales office which has been operating each and every day with reduced staff. Jim as far as the impact you want to make take that

Yes, right now, I think it's hard to speculate because, really, we just have a delay and some of our people coming back to work. We have sufficient inventories. It's really about what the delay and the demand for shipping might turn out to be. And that's really what how we kind of, we just have to see kind of every two weeks and how it plays out throughout Q1.

There clearly will be a slowdown in demand from our customers as well as their operations are equally impacted. And I think that, that's something that we anticipate. But yet, at this point cannot quantify. So, we're monitoring the situation obviously very closely. And depending on how long this situation drags on, the impacts to the supply chain down the road in the future is something that we have to watch. In the near-term, we have ample inventory for customers. And again, one of factories is operating unrestricted and the other one line is operating, and the other line should be operating here by the end of this week actually.

And then maybe then the second part of your question was. Do you see soybean demand backing up? And what are the ramifications on some of the co-products that we sell? I think if you witnessed over the last month to two months, at least, soybean oil, corn oil, palm oil have all been significantly up due to some constraints in those marketplaces. And so we've seen some softening of corn gluten meal prices. Again, we're just going to watch how much anticipated demand I think can back up on soy and whether or not there's decisions to crush that and whether or not that impacts the availability of both soy meal, as well as soy oil. But right now it seems like a lot of crushing is going towards just kind of produce more soy oil, because that's the better part of the arbitrage.

And as it relates the guidance, you have a bit wider range you guys gave a wide range last year is that uncertainty around coronavirus contemplated in the guidance at all as we look towards the lower end of the guidance range. And then one more question on guidance just generally your outlook for net corn costs that's incorporated into the guidance for 2020?

So I think with our guidance when we were obviously assembling that and employing that together and corona was not a kind of a factor on the horizon. So, generally, it does not include any kind of significant or delayed impacts, if those who believe in materialize. As Jim mentioned, we're up and running in one of our facilities and the other facility has at least one production line running. With regard to more of our outlook for co-product values, as it relates to het cost of corn. I assume that the scope of that was really kind of more around North America, or U.S., Canada. When we pull together our estimates, we're really doing that kind of more back in December, November-December when those prices are in place. We see the run up in some of the co-product values very recently. We're waiting to see, if those have a kind of an enduring longevity throughout the year. So, that's really not, our guidance really on the co-products is really more kind of based on what we might see as kind of more of the three year average during the fourth quarter.

Okay, perfect. Thanks, best of luck.

I do think it's important to point out regarding China that it's between 2% and 2.5% of our sales overall as a company. So just help put it in perspective.

Our next question comes from Heather Jones with Heather Jones Research.

Good morning. Thanks for the question. Just as a follow-up on Ben's questions. I just wanted to sort of condense what you guys said. So, there's no impact from coronavirus built into your guidance because you pulled it together prior to that becoming a bigger factor, but it would need to spillover given the relative size of China to your business. We would need to see the spillover impact into Europe, South America etcetera for it to be meaningful, in your opinion, am I understanding your commentary correctly?

I think given the fact that we're having the call today, and we finalized everything in prep for this call that it doesn't, as Jim said, take into account any significant or meaningful impact of coronavirus. But it does take into account, what we know as we sit here today, as we have provided guidance, which does take into effect some impact, as I just described in relationship to our operations for example. So, that's what I would say about, how we view coronavirus and again, China is about 2% to 2.5% of our overall sales of a company. So hopefully that helps with the answer and it's just too early right now to fully assess the total impact.

That is helpful. Moving to North America, which is obviously the big driver of your business. I was wondering if you could give us a sense of the visibility you have into your guidance there. You mentioned that it will -- my take away from your comments was that, your guidance doesn't give a threat to the recent, very recent run we've seen in vegoil prices, but more like a Q4 average. But just what could yield upside and downside risk to your North American business based upon what you know about the contracting season? What you know about your positioning on corn cost? Can you just highlight the biggest risk upside or downside to that North American outlook?

Sure, well, let me start and I'll let Jim make some comments. So first of all, we're seeing low single digit average price increases across North America and flat to low single digit change in the cost of corn, and thus margins are flat to slightly expansive. We expect high fructose corn syrup, sweetener volumes to be down in line with their historical norm of trending down, between 1% and 2% flat to slightly positive volume growth across the rest of the North American business and continued mid-single digit volume growth for specialties. We anticipate that quarter basis will continue to be elevated during the first half of the year until expectations for the new corn crop emerged. And clearly, as it relates to risks, we're assuming a return to an average corn crop with normal planting, on time planting, et cetera. I would say volumes are always a risk in North America to our business. But we're right now assuming, taking into account what I just talked about in relationship to the volume trends that we're seeing. So, Jim, I'm going to turn it over to you to have any additional color commentary perhaps on co-products or co-product recoveries?

Yes, I mean, I think as we thought about that, you're expecting very modest co-product value recovers. As you know, we do not see any trade flows between U.S. and China resuming was any kind of positive effect quickly throughout the year.

Okay. And I just, I don't want to belabor that point, but I just want to see what you guys are seeing versus what I may be seen. And you made the point that corn gluten meal values have traded down some, but there's been a very sizable rally in vegoil values. And so, looking at cash corn which does have some elevated basis in it, but relative to cash by product values, there's been a pretty nice recovery in that rate of recovery from, call it early Q4 to the present. Is there something that's limiting you guys from seeing that or you're just being conservative and assuming that may not continue for the rest of the year? So, help me to understand how you all are thinking about it?

Well, I think obviously, there's 12 months in the year and just necessarily the January rise and two the value doesn't make kind of for the full year forecast. Part of the run up in corn oil has been due to a little bit of constrained supply. So I think that has potentially some temporal effect to it, at least in the U.S. Meal prices are -- have come up, but there is an abundance -- we'll see at least the soya meal in the marketplace. And so, we're kind of measured in our outlook for that value. And fee values usually follow corn, so corn has been trading in a pretty tight range with regard to kind of the outlook for the layout of corn for 2020. So, we don't see necessarily something where we see all of the co-product values all rising because of continued tightness in the market or higher demand. So, we're just looking -- as I said, we expect kind of modest co-product value recoveries because we just don't see a lot of the big moves yet from demand pulling from China.

Okay. My final question is. Just wonder if you could give us your updated thoughts on what you're seeing in the Brazilian economy? The currency has been incredibly weak of late, but that could be attributable to just a risk off attitude and all, but like what are you seeing on the ground as far as trends there?

Yes, let me comment. So for South America in general, I mean, we expect low-single digit volume growth in Brazil. And basically on the ground there, we are seeing very strong specialties growth. We highlighted that for quarter four. And so, we're seeing a lot of activity by customers that are formulating very much on trend ingredients -- with on-trend ingredients, that we supply, cater to the latest trends. And so, we're seeing, I guess, I would say strong economic activity or pickup in economic activity in Brazil. And so, we expect operating incomes to be up in the region primarily driven by Brazil volumes and lower net core costs as well as benefits of Cost Smart across the region.

Our next question comes from Brett Hundley with Seaport Global.

My questions are going to focus on specialty part of your portfolio. Zallie, I think you said in your prepared remarks that during Q4, texture grew low-single-digits. Thanks for those comments by the way. If that is the case, I thought texture might be growing a little bit more than that. And so, I just wanted to revisit that comment with you and see if there was anything during the period that might have weighed on that and just get your continued outlook for texture specifically?

No, I don't think there's anything weighting on per se. I think that texture will be made up by our starch-based texturizers portfolio, our clean and simple ingredients, and our approach to customer co-creation in food systems. So all of those customer engagements continue to go very well, and one of our areas of focus is to diversify beyond corn. And so, we really are seeing growth in our tapioca franchise as well as our potato starch franchise. And I'm also pleased to say one of the things we didn't really highlight explicitly in the prepared comments was that, our rice investment in Thailand will also be commissioning in quarter two of this year. So those are all very strategic purposeful investments to diversify beyond corn, which is the main staple. But with trends towards green free for example, we see increased demand for those ingredients and they also provide different functionalities, complimentary functionalities for products like snacks and snacking, which is growing. And so, we feel very good about our starch-based texturizers portfolio as well as the hydrocolloids so that we have now in our portfolio to compliment starch-based. And then, we're very excited obviously by what protein is going to offer also, as it relates to rounding out texture additionally with the protein fortification as well.

And staying on the topic of texture, we've talked to some other -- sorry, we talked to some other, what I call adjacent ingredients peers of yours and it does sound like more participants are interested in entering or expanding on their texture capabilities. And I'm not necessarily asking this question from a competitive threat standpoint, but I am interested in understanding, if you believe that texture capabilities are becoming more sought after by the broader ingredient space as a whole?

So, I think that one of the things that the -- as an ingredient supplier, you want to be in a position to do is be a problem solver and to do that with speed. And so, texture is one of the most important qualities and attributes for the overall sensorial experience of a food product. And so, we feel a very good about who we are in the space of texture being the broadest and deepest in the world of specialty starches. In addition having now capabilities and hydrocolloids as well, with a very purposeful focus on customer co-creation, which is all about working with select customers in a very concentrated time period to go from concept to, to the shelf, and we are being perceived as a more complete formulation and solutions provider in that regard. And so, texture will continue to be a hallmark of our value proposition that we bring to customers.

Thank you for that and then just one more on specialty. This has more of a regional focus, but we aim to derive your regional specialty performance based in part on core and specialty performance from some of your peers, but we back into strong specialty performance for Ingredion in Latin America, similar to what you announced this morning. And then we also back into solid growth, solid performance in Asia and Europe. In North America more recently, we're backing into like low-single digit growth for your specialty. And I wanted you to weigh in on whether we're in the right ballpark there and whether or not you can go into some detail and describe the state of your specialty portfolio in North America today and how these dynamics might change in coming periods as you place investment in adjacent areas? Thank you.

So just going back to a comment I made earlier. We indicated that for North America, we're seeing continued mid-single digit volume growth for specialties in our guidance. As it relates to North America, one of the things we're most excited about is our new plant-based protein capacity expansion and commissioning of the facility in Nebraska, which will be available in the second half of the year. And we expect to see incremental net sales and contributions beginning to cover the startup costs of that facility in the second half of this year. We're seeing very strong customer interest in customer engagement as this new ingredient platform comes to market. And so, we're very excited about the specialties prospects for pulse protein isolates as well as flowers and concentrates. And again, the complementing formulation capabilities that provides to our customers in North America.

Brett I'd also add that, within North America, it's our largest specialty book of business as well as we haven't talked much towards food systems that in and of itself, just how we look at gums as a growing part of this business as well as sugar reduction.

We also had a very strong quarter in Mexico for specialties growth, which is included in our North America business. So, if that gives you even a little bit more color in relationship to overall North American specialties.

Our next question comes from Ken Zaslow of Bank of Montreal.

Coupe of questions. One is, last quarter, your FX more aligned with your price -- your pricing I'm sorry, more aligned with your FX and you offset more. This one -- there seemed to be a widening spread. I would have thought that it would have been continued to narrow. Can you talk about at what point do you expect pricings overtake the FX headwinds. And how do you think about that?

Well, this quarter as to highlight, our price mix was in Q4 was $68 million to the positive. FX was a headwind of $56 million. So, we do see some price mixed in Q4 that was greater than the FX headwinds. I think what you're seeing is that, in South America, we're seeing global inflation and pricing kind of ahead of that, which is catching up with that past FX weakness where you had some newer FX softening would have been in some of the Asia pack countries. And as we noted, Ken, you're trying to gain that price on weakness in the Korea one is challenging and I'll take time as one example.

Okay. Actually in North America, but okay, but do you think that there will be a point in time that the excellent North America, the FX, or the pricing will more than offset because history has shown that that's what you do. So, I just want to make sure that things have not changed, or do you think things have gotten a little bit more complicated with South Korea as well as the EU that maybe not see that as much, but that is what I would expect over time, is that fair?

Yes, absolutely. Let me just take that and again, I just want to draw you back to my comments. South America really represented the biggest challenge for us, as it relates to pricing to offset foreign currency weakness. And I want to remind you, that that region experienced $200 million of foreign currency weakness in the year, which was offset by $151 million of pricing actions. Now, one of the things that I think we all observed is the steep evaluation of the Argentine peso. So we have been in ketchup mode there, but I also pulled out the efforts of our team who have done a fantastic job of moving price there. And we are seeing very good progress in relationship to their pricing actions to offset that. Just when we thought the Brazilian real, based on everything you read, and are observing and relationship to the economy, and political stability and pension reform and fiscal reform getting passed, yet, we have been somewhat surprised to see some continued weakness in the real. So again, pricing is a lever that we pull, and we are confident that we're going to continue to make progress in South America. And I call out South America because again, it represented $200 million of that $292 million in the year. And I think our team has done actually a very, very good job. The problem is. It's been unabated in relationship to the foreign exchange headwinds that we faced. And in fact, Jim called out, I believe, in our guidance, that we anticipate foreign exchange weakness, which is factored into our guidance of an additional $30 million to $50 million to the impact of net sales. So hopefully that helps Ken.

It does. The second question I have is, when I think about your capital projects, that coming online on 2020, can you talk about the incremental EBITDA that's associated with that, that we can think about in 2020 and in 2021 and beyond? How do we think about that?

Ken, as Jim mentioned that let's take plant-based proteins in North America as an example. So, we're completing the production lines. Right now, we're running product through and we're commissioning. That commissioning timetable can take six months, three months, six months, there's at least a period in there where we have products that doesn't need to be approved by various government regulatory agencies. And then also customers are doing their own kind of audits of the plants and other product quality. So, right now, we have the full costs of running those -- running our South to city facility will hit our P&L in 2020. We'll start to see sales more in the second half and the contribution from those sales will start to contribute to the incremental EBITDA that you're questioning. So, right now, it's actually a cost impact to the P&L when we're in commissioning mode. As we move more towards 2021, and sales build as we move through and fill the capacity, then we'll see the contribution margins offset. So we get kind of a swing impact on the P&L but more towards 2021.

I would say just to answer it in kind of totality, it's certainly plant based proteins is a major investment for us, but there is the IOs investment, there is the rice investment, there are other investments that we've made across global specialties network. And I would say that, because those investments are commissioning in quarter 2, for the most part. We've been pretty modest, I guess in our EBITDA contribution in calendar year 2020. But certainly we expect additional contribution, significant contribution in 2021.

In 2021 like what would you expect a return on capital of north of 15%, 20%? Or as kind of deals, would you expect it to be just still modest? And just kind of saying that just one last question I'm sorry.

We spend a lot of focus. So when we add this capacity, generally our capacity takes anywhere as short as 3 years and as long as 5 years to fill. So we're looking usually in a run rates or 20% and 40%, 60% of the capacity filling, because we've added capacity ahead of market demand. And our sales teams are working with customers to design in the highly functional product that's coming off of our new capacity. So, we generally see kind of hitting the ROIC or paybacks on these projects somewhere around years three, year four, when we have between 60% and 80% of our capacity filled. So, that's pretty typical of kind of larger capital investments that we're putting in to expand their texturizers portfolio. I think in the case of plant-based proteins that might be shortened down in blue that horizon.

And then just a clear clarification, somebody asked it. I just didn't understand the answer. The difference between the low end and the high end of the guidance; what are the key factors? And I'll leave it there.

Yes. So, I think the high end of the guidance would be that, we see still kind of modest volume that we would see kind of continued co-product strength, right. As I said, kind of the center part of our guidance is that really just the very modest co-product value recoveries in North America, if the values of the co-price continue throughout the year evidence and I think that would lean a little bit more towards outside in our guidance. I think if we have a little bit more filling up the capacity in some of our specialty investments faster than what we've been what is the horizon I just described? I think that would lend itself to the upside. And then, we really are not seeing any kind of -- in South America with respect to Argentina, right now, we have an assumption for a weakening Argentina peso. As I mentioned, we have greater than $10 million expected from hyperinflation accounting that lands in our financing costs is the revalue of the net assets in Argentina to U.S. dollars. So under hyperinflation, accounting that does impact us in our income stream. And so right now we're seeing at least some weakening of the peso. I think if the peso -- if the governments of different actions that really collapse the peso then we'd have any more downside risk.

And then coronavirus, I guess, on the downside also would be factor into the low end of the guidance.

Yes.

Next question comes from Robert Moskow with Credit Suisse.

Couple more questions on the guidance. I think in the first half of 2019, you had some weather-related costs in North America. That should set up a pretty easy comparison, I would think for 2020, especially if your pricing is rolling through rather quickly. Can you give us an estimate as to what those costs were in '19? And it was it fair to say therefore, that your earnings growth in 2020 would be front half loaded.

Yes, I'll take it. Hey, Rob. With regards to North America, when we did have a little bit of weather related, it wasn't significant as much. I think it was more because we had some rail lines freezing and some delays in terms of putting products through and there was nothing anywhere close to 2014 or some more significant years. You're correct in that it does set up for a slightly easier lap. I think more importantly, with regard to North America would have been where the co-product values were and kind of what the cost of corn was relative to pricing. So, it looks like as we anticipate 2020, slightly higher growth corn and basis. And we've priced to really kind of capture that back. We're really kind of seeing margins really flat maybe just slightly expand in North America. So I don't think it's a significant bump up in the first half where we would continue to see kind of your modest growth and in North America for the first half.

Okay. And in sweeteners you're expecting the normal 1% to 2% annual decline in demand. I would argue that pricing power this year was enabled by the fact that you've closed down Stockton. But if 1% to 2% declines persist, how does that set up for pricing going forward for 2021-2022? How close are we to get stability right now in supply demand for sweeteners in North America industry-wise?

Well, so first of all, the decline that I refer to was specifically to HF not for total sweeteners as far as that declined. So, I think that the action that we took with Stockton has certainly tightened our network to very high capacity utilization. So we feel very good about where we're at, for 2020. It's obviously hard to predict what's going to happen going forward in 2021 and beyond related to where sweeteners have declined over the last decade, and where that will, will go going forward. It's just hard to predict. So I think we just feel very good about where we're at right now with our network and our capacity utilization based on the actions that we have taken.

I'll Follow up one more time, I mean, I don't think in Ingredion has provided a broader sweetener volume kind of growth estimate for the industry or I don't think internally either. So if HF is declining 1% to 2%, is it fair to say that broader sweeteners are, I don't know flat, is it better than that over the past several years? Is there a way to know?

Yes, I think that I think that broader sweeteners as it relates to glucose syrup, for example, are growing in line with GDP growth, maybe 1% to 2% per year, depending on the application.

Yes, maybe lower, its right around, it depends on pop growth and per capita on which country you're in, but you definitely see glucose when you see dextrose as sweeteners. Some of those lend themselves to kind of unique segments and some of them also live with themselves to kind of building back ball for or some texture roles. And so we do see those kind of anywhere with flattish to modestly up depends on really which country you're in.

Next question comes from Adam Samuelson with Goldman Sachs.

I just had a few clarification questions around the guidance. First, the increase in corporate expense, $15 million to $28 million or so, how much that is actual investment in the business versus earnings coming out of, our costs coming out of the segments, if you break those two out, please?

Yes, sure. About, I think it's about a third is cost moving from segments into center about a third is specific investments and enhancing digital and driving some of our go-to-market efforts centrally, and a third is kind of merit and inflation and kind of bonus reset normal kind of wage costs comp change.

Okay, that's helpful. And then in whether it's the total company or by region, specifically in North America, what are the assumed net Cost Smart kind of earnings contribution in 2020?

Yes, so right now, we're not necessarily going through and disclosing by region kind of where Cost Smart savings are. We do have targets. We have targets specifically for both, the SG&A or the operating expense side as well as the cost of sales and side. And obviously, what we're doing is each initiative. Each project has a bit of a life of its own in terms of getting to the hypothesis --from hypothesis to implementation to action. And so we just want to be thoughtful as we roll into those out. So add them all up to deferral on answering that question.

And then I guess the last one, just the guidance on cash flow from operations. I mean, one, you exceeded the cash from op guidance for 2019. But then if I look at the 2020, guidance, you're actually guiding cash from us, potentially down at the lower end versus the net income guidance, which is functionally flat at below and can you just bridge between the changes in net income and cash from ops?

So, essentially, it's and at the as we close out 2019, I think we had some favorability and accounts payable we were anticipating that accounts payable would impact working capital to a greater degree. As we look forward to 2020, we're very much focused as a team on our working capital change. And we see still -- we're very much want to tighten working capital, but as we grow revenue, we're going to have more obligations with customers in form of accounts receivable as well as inventories. And so, while that changing working capital will be a drain on cash from ops because the top line is higher, we're still trying to reduce the rate of that change. And that's what impacting basically our guidance as we think about the cash from ops. We're reducing capital commitment year-over-year too, which we highlighted call.

I'm not showing any further question at this time. I'd like to turn the call back over to our hosts.

Okay. Well, I would like to thank you for your time today, and Jim and I hope to see many of you at CAGNY next week in Boca Raton. And with that, that concludes our call today. Thanks very much.

Ladies and gentlemen, this does conclude today's presentation. You may now disconnect and have a wonderful day.